Precision Functional Brain Mapping in Psilocybin

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

March 19, 2023

Study Completion Date

March 19, 2023

Conditions
Psilocybin
Interventions
DRUG

Psilocybin

Psilocybin is a naturally occurring psychedelic compound produced by psilocybin mushrooms, and has been shown to have antidepressant and anti-anxiety effects after one dose of 25 mg. Common side effects are slight elevations in blood pressure and heart rate. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.

DRUG

Methylphenidate

Methylphenidate is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is used as an active control for this study because it is metabolized similarly to psilocybin and has similar effects on heart rate and blood pressure. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.

Trial Locations (1)

63110

Washington University, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER